Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04487860 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
A Phase 2 study of Non-segmental Vitiligo, sponsored by Ache Laboratorios Farmaceuticos S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 327
- Enrollment target
- 20
- Study locations
NCT04487860 is a Phase 2 study of Non-segmental Vitiligo that has completed, run by Ache Laboratorios Farmaceuticos S.A.. The registered enrollment target is 327 participants, above the 161-participant average among 5 other Non-segmental Vitiligo trials with a reported enrollment target (103% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT04487860, a Phase 2 study of Non-segmental Vitiligo, has completed, sponsored by Ache Laboratorios Farmaceuticos S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 327 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AS012
Study Locations (20)
Florida
- Sun Pharma Site 01 - Brandon
- Sun Pharma Site 06 - Fort Lauderdale
- Sun Pharma Site 04 - Miami
- Sun Pharma Site 05 - Miramar
- Sun Pharma Site 10 - Ormond Beach
California
- Sun Pharma Site 09 - Fremont
- Sun pharma site 30 - Los Angeles
Louisiana
- Sun Pharma Site 12 - Baton Rouge
- Sun Pharma Site 13 - New Orleans
Rhode Island
- Sun Pharma Site 29 - East Greenwich
- Sun Pharma Site 08 - Warwick
Texas
- Sun Pharma Site 03 - Dallas
- Sun Pharma Site 16 - Pflugerville
Arizona
- Sun Pharma Site 15 - Phoenix
Arkansas
- Sun Pharma Site 02 - Bryant
Indiana
- Sun Pharma Site 14 - West Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04487860
The ClinicalTrials.gov registry entry for NCT04487860 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 161-participant average among 5 other Non-segmental Vitiligo trials with a reported enrollment target (103% higher). The listed sponsor is Ache Laboratorios Farmaceuticos S.A., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04487860 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT04487860 about?
NCT04487860 is a clinical study titled "Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo". This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.
What is the current status of trial NCT04487860?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 327 participants. The study started on 2021-01-13. Estimated completion is 2023-02-27.
What conditions does trial NCT04487860 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo.
What interventions are being tested in trial NCT04487860?
The interventions under investigation include: Placebo (DRUG), AS012 (DRUG).
Who is sponsoring clinical trial NCT04487860?
This trial is sponsored by Ache Laboratorios Farmaceuticos S.A., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04487860 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-segmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
RECRUITING · Phase 2
-
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
RECRUITING · Phase 2
-
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
ACTIVE NOT RECRUITING · Phase 2
-
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.